The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 112, Issue 5, 2005, Pages 579-583

  Hellgren, M ^a,c   Johansson, S ^b   Eriksson, U G ^b   Wahlander K ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BREAST MILK; CAUCASIAN; DIZZINESS; DRUG EXCRETION; DRUG HALF LIFE; DRUG MILK LEVEL; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; HUMAN; HUMAN EXPERIMENT; LACTATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; PUERPERIUM; SIDE EFFECT; SINGLE DRUG DOSE; SWEDEN;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BREAST FEEDING; FEMALE; GLYCINE; HUMANS; LACTATION; MILK, HUMAN; POSTPARTUM PERIOD; PUERPERAL DISORDERS; THROMBIN; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 18744406294     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00494.x     Document Type: Article

References (33)

1. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1256-1265.
2. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic drugs during pregnancy. Chest 2001;119:122S-131S.
3. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 2001;52:708-710.
4. Orme ML, Lewis PJ, de Swiet M, et al. May mothers given warfarin breast-feed their infants? BMJ 1977;1:1564-1565.
5. McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983;103:325-327.
6. Brooks C, Rutherford J, Ramsay MM, Gould J, James DK. Warfarin dosing in postpartum woman: a case-control study. Br J Obstet Gynaecol 2002;109:187-190.
7. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopaenia - alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 2002;28:439-445.
8. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
9. Blann AD, Landray MJ, Lip GYH. ABC of antithrombotic therapy: an overview of antithrombotic therapy. BMJ 2002;325:762-765.
10. Gustafsson D, Nyström J-E, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-181.
11. Eriksson UG, Bredberg U, Hoffmann K-J, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003;31:294-305.
12. Eriksson UG, Bredberg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003;59:35-43.
13. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42:765-777.
14. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 2003;31:645-651.
15. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-118.
16. Boström SL, Hansson GFH, Kjaer M, Sarich TC. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin, on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis 2003;14:457-462.
17. Sarich TC, Eriksson UG, Mattsson C, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002;87:300-305.
18. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997;78:1404-1407.
19. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999;94:187-197.
20. Mikulski A, Elg M, Gustafsson D. The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thromb Res 2001;101:477-482.
21. Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TG. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998;31:345-351.
22. Sarich TC, Osende JI, Eriksson UG, et al. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost 2003;1:999-1004.
23. Wåhlander K, Lapidus L, Olsson C-G, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002;107:93-99.
24. Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, for the THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;1:41-47.
25. Schulman S, Wåhlander K, Lundström T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721.
26. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-1447.
27. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003;89:288-296.
28. Eriksson BI, Agnelli G, Cohen AT, et al. on behalf of the EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-2496.
29. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-655.
30. Francis CW, Berkowitz SD, Comp PC, et al. for the EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement: EXULT A. N Engl J Med 2003;349:1703-1712.
31. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698.
32. Larsson M, Ahnoff M, Abrahamsson A, et al. Determination of ximelagatran, an direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783:335-347.
33. Lawrence RA, Lawrence RM. Breastfeeding: A Guide for the Medical Profession. Philadelphia (Pennsylvania): Mosby, 1999.